Compare SRRK & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | ACT |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.8B |
| IPO Year | 2018 | 2021 |
| Metric | SRRK | ACT |
|---|---|---|
| Price | $49.84 | $42.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | ★ $55.64 | $42.67 |
| AVG Volume (30 Days) | ★ 1.7M | 240.4K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | N/A | ★ 3.43 |
| EPS | N/A | ★ 4.52 |
| Revenue | N/A | ★ $1,235,827,000.00 |
| Revenue This Year | N/A | $4.22 |
| Revenue Next Year | $544.77 | $2.33 |
| P/E Ratio | ★ N/A | $9.32 |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $27.07 | $33.94 |
| 52 Week High | $51.63 | $44.80 |
| Indicator | SRRK | ACT |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 57.71 |
| Support Level | $41.07 | $39.43 |
| Resistance Level | N/A | $42.80 |
| Average True Range (ATR) | 2.21 | 0.82 |
| MACD | 0.51 | 0.20 |
| Stochastic Oscillator | 82.19 | 70.99 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.